A Phase 3 interventional study of Saxagliptin and Metformin XR in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 139 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 12 that started in 2012, is one of 27 in phase 3, and was the 39th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,282 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 16th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2012, is one of 119 in phase 3, and was the 210th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Saxagliptin · Drug: Metformin XR · Drug: Placebo matching with Dapagliflozin
Drug: Metformin XR · Drug: Dapagliflozin · Drug: Placebo matching with Saxagliptin
Drug: Saxagliptin · Drug: Metformin XR · Drug: Dapagliflozin
Tablets, Oral, 5mg , Once daily, 24 weeks
Also known as: Onglyza
Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Also known as: Glucophage XR
Tablets, Oral, 10mg , Once daily, 24 weeks
Also known as: BMS-512148
Tablets, Oral, 0mg, Once daily, 24 weeks
Tablets, Oral, 0mg, Once daily, 24 weeks
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.
Time frame: Baseline (Week 0) and at Week 24
Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])
Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.
Time frame: Baseline (Week 0) and at Week 24
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.
Time frame: Baseline (Week 0) and at Week 24
Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])
Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.
Time frame: At Week 24
Adjusted Mean Change From Baseline in Body Weight at Week 24
Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.
Time frame: Baseline (Week 0) and at Week 24
| Milestone | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR |
|---|---|---|---|
| Started | 176 | 179 | 179 |
| Completed | 161 | 160 | 169 |
| Not completed | 15 | 19 | 10 |
| Withdrew: Reason 'other' in the protocol | 0 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 8 | 6 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Discontinue study treatment | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 6 | 8 | 5 |
| Withdrew: Poor/non-compliance | 1 | 0 | 0 |
HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.
| % HbA1c | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 | -0.88 (-1.03 to -0.72) | -1.20 (-1.35 to -1.04) | -1.47 (-1.62 to -1.31) |
Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.
| MG/DL PPG | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF]) | -35.6 ± 3.510 | -70.4 ± 3.538 | -79.6 ± 3.426 |
Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.
| mg/dL | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -14.0 (-19.6 to -8.4) | -31.7 (-37.3 to -26.2) | -37.8 (-43.2 to -32.3) |
Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.
| % of Participants | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR |
|---|---|---|---|
| Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]) | 18.3 (13.0 to 23.5) | 22.2 (16.1 to 28.3) | 41.4 (34.5 to 48.2) |
Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.
| Body weight Kg | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Body Weight at Week 24 | 0.00 (-0.48 to 0.49) | -2.39 (-2.87 to -1.91) | -2.05 (-2.52 to -1.58) |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAXA + MET | — | 6/176 (3.4%) | 0/176 (0%) |
| DAPA + MET | — | 2/179 (1.1%) | 0/179 (0%) |
| SAXA + DAPA + MET | — | 2/179 (1.1%) | 0/179 (0%) |
| Event | SAXA + MET | DAPA + MET | SAXA + DAPA + MET |
|---|---|---|---|
| UMBILICAL HERNIAGastrointestinal disorders | 1/176 | 0/179 | 0/179 |
| CHEST PAINGeneral disorders | 1/176 | 0/179 | 0/179 |
| TOOTH INFECTIONInfections and infestations | 1/176 | 0/179 | 0/179 |
| PATELLA FRACTUREInjury, poisoning and procedural complications | 1/176 | 0/179 | 0/179 |
| HYPERKALAEMIAMetabolism and nutrition disorders | 1/176 | 0/179 | 0/179 |
| ARTHRITISMusculoskeletal and connective tissue disorders | 1/176 | 0/179 | 0/179 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 1/176 | 0/179 | 0/179 |
| DEEP VEIN THROMBOSISVascular disorders | 1/176 | 0/179 | 0/179 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/176 | 0/179 | 1/179 |
| PANCREATITIS CHRONICGastrointestinal disorders | 0/176 | 0/179 | 1/179 |
| Age, Continuous(Years) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| Mean | 54.6 ± 9.6 | 53.5 ± 9.7 | 53.4 ± 9.8 | 53.8 ± 9.7 |
| Age, Customized(participants) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| <65 years | 148 | 158 | 160 | 466 |
| >=65 years | 28 | 21 | 19 | 68 |
| Sex: Female, Male(Participants) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| Female | 82 | 90 | 94 | 266 |
| Male | 94 | 89 | 85 | 268 |
| Race/Ethnicity, Customized(participants) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| White | 121 | 131 | 120 | 372 |
| Black african/american | 22 | 16 | 22 | 60 |
| Asian | 11 | 10 | 12 | 33 |
| Other | 22 | 22 | 25 | 69 |
| Body Mass Index (BMI)(kg/m^2) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| Mean | 31.8 ± 5.142 | 31.46 ± 5.321 | 31.76 ± 4.787 | 31.67 ± 5.080 |
| T2DM duration(years) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| Mean | 8.2 ± 5.52 | 7.4 ± 5.40 | 7.1 ± 5.04 | 7.6 ± 5.33 |
| HbA1c(%) | Arm 1: Saxagliptin+Metformin XR+Placebo | Arm 2: Dapagliflozin+Metformin XR+Placebo | Arm 3: Saxagliptin+Dapagliflozin+Metformin XR | Total |
|---|---|---|---|---|
| Mean | 9.03 ± 1.05 | 8.87 ± 1.16 | 8.92 ± 1.18 | 8.94 ± 1.13 |
Showing the first 100 of 139 sites across 8 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Dapagliflozin